93 results
PRE 14A
ONCR
Oncorus, Inc.
12 Jun 23
Preliminary proxy
6:33am
in this proxy statement regarding tax consequences are general in nature.
We have not requested a ruling from the IRS with respect to the anticipated … .
The description of the Dissolution contained in this introductory section is general in nature and is subject to various other factors and requirements
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
).
In October 2022, Oncorus published preclinical data in Nature Communications highlighting the potential of its self-amplifying RNA platform as a novel
8-K
vyns3t
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
8-K
EX-99.1
zbswm
2 Nov 22
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:11am
8-K
EX-10.1
lfrec3n3cv4wwko
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
8-K
EX-4.1
ixl4f
5 Apr 22
Entry into a Material Definitive Agreement
7:10am